Panel · Use case · Brand & Marketing

Launch Plan Red Team.

LiveRed Team Review

Stress-test a specialty product launch plan from competitive, payer, brand and market access angles before it is approved.

Plan under testA specialty product launch plan

AnglesEcosystem, evidence, brand, access

ReaderLaunch and commercial leads

Not askedA revised forecast

DepthStandard, four seats

Launch Plan Red Team is a ready-made use case for Brand & Marketing. It ships under the Red Team Review template.

For brand and commercial leads. You get the position under test, a verdict, the challenges by angle, which survive, what would have to be true and where the plan is weakest. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

Where does the launch plan for a specialty product fail, before it goes to the executive committee?

Who attacks

Specialty launches depend on a few payers and pharmacy benefit managers, which the FTC found to be concentrated. The red team starts from access.

Seat	How it attacks	What it works from
Ecosystem Intelligence Orchestrator	Competitor launches, channel partners and the players who control access.	Public company and market records.
HEOR Evidence Lead	Whether the evidence package meets what payers ask in a formulary submission.^{2Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}	The AMCP Format.
Global Brand Lead	Whether the positioning survives the label and the evidence.	Label and research.
Global Market Access Director	Whether the access assumptions hold given the concentration of managers.^{1U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}	The FTC’s report on pharmacy benefit managers.

What the red team does

Concentration is a risk. The FTC reported that the three largest managers processed nearly 80 percent of prescriptions in 2023. A plan that assumes broad coverage from a few contracts depends on a few decisions, and the report says so.^{1U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}

The dossier is the test. The evidence seat checks the package against the AMCP Format, which payers use as a common frame.^{2Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}

Tripwires. The report names the early signals that would show the plan is failing, such as the first formulary decisions, and what to do on each.

Recommended length

Standard

Four angles can break this plan. Standard depth gives each a seat, scores the challenges and lists mitigations and tripwires in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the red team tests

The red team lists the assumptions the plan relies on and says what would break each. Examples for this plan:

The product will be covered at launch under a standard utilization policy.
No competitor will launch a comparable product within the window.
The specialty channel will have capacity at launch.

Standards, guidance and sources

Frame

FTC, interim staff report on pharmacy benefit managers, July 2024.^{1U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024.}
AMCP Format for Formulary Submissions, version 4.1.^{2Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any assumption that a coverage decision will follow the launch timeline, any competitor event no seat checked, and any tripwire with no owner.

What arrives

The position under test
Verdict
The challenges, by angle
Which challenges survive
The pre-mortem
What would have to be true
Mitigations and tripwires
Where the position is weakest

What it will not do

It stays adversarial and does not defend the plan. It is a stress test by AI specialists and not a vote of human experts, and the decision stays with you.

It does not forecast sales.

It does not defend the plan. Defenses appear only as the status of an attack.

It does not invent an attack. Each challenge rests on a cited fact or is marked as a gap.

It is not a vote of human experts. Every seat is an AI specialist, and the report says so.

References

[1] U.S. Federal Trade Commission. Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies. Interim staff report, 9 July 2024. Figures as given in the FTC’s press release and search excerpts; the report was not read in full.
[2] Academy of Managed Care Pharmacy. AMCP Format for Formulary Submissions, Version 4.1. December 2019. Scope and status as given in AMCP’s release; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.